Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Pharmaxis Ltd ( (AU:SNT) ) has provided an update.
Syntara Limited has announced promising results from a subgroup analysis of its SOLARIA2 trial, which evaluates the safety and effectiveness of the drug SNT-6302 for treating skin scarring. The findings reveal that SNT-6302 significantly improves scar vascularisation and extracellular matrix remodelling, making scar tissue structurally and biologically closer to normal skin, as confirmed through advanced imaging technology. These developments position Syntara to advance its clinical plans and explore broader applications for scar prevention and treatment, potentially reshaping future scar management approaches.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company focused on innovative treatments for skin scarring. Their primary product involves topical pan-lysyl oxidase inhibition, aiming to improve cosmetic and functional outcomes in scar management.
YTD Price Performance: -11.25%
Average Trading Volume: 5,117,834
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$112.1M
For an in-depth examination of SNT stock, go to TipRanks’ Stock Analysis page.
